Shaping of the tumor microenvironment: Stromal cells and vessels

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 3-13

  Blonska, Marzenna ^a   Agarwal, Nitin K ^a   Vega, Francisco ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Angiogenesis; Hedgehog signaling; Lymphoma microenvironment; NF B signaling; Stromal cells

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CXCL13 CHEMOKINE; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4;

ANGIOGENESIS; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER GROWTH; CARCINOGENESIS; CELL CULTURE; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR SECRETION; CYTOARCHITECTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM CELL; FIBROBLASTIC RETICULAR CELL; FOLLICULAR DENDRITIC CELL; IMMUNOCOMPETENT CELL; LYMPHOMA; MACROPHAGE; MAST CELL; MESENCHYMAL STROMA CELL; NURSE LIKE CELL; PROTEIN EXPRESSION; RETICULUM CELL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; CELL SURVIVAL; ENDOTHELIAL CELLS; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84942295924     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.03.002     Document Type: Review

References (125)

1. Scott D.W., Gascoyne R.D. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014, 14:517-534.
2. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
3. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
4. Huntzicker E.G., Estay I.S., Zhen H., Lokteva L.A., Jackson P.K., Oro A.E. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev 2006, 20:276-281.
5. Aberger F., Ruiz I.A.A. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol 2014, 33:93-104.
6. Singh R.R., Kim J.E., Davuluri Y., Drakos E., Cho-Vega J.H., Amin H.M., et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 2010, 24:1025-1036.
7. Singh R.R., Kunkalla K., Qu C., Schlette E., Neelapu S.S., Samaniego F., et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011, 30:4874-4886.
8. Agarwal N.K., Qu C., Kunkalla K., Liu Y., Vega F. Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem 2013, 288:15390-15401.
9. Qu C., Liu Y., Kunkalla K., Singh R.R., Blonska M., Lin X., et al. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-kappaB activation in diffuse large B-cell lymphoma. Blood 2013, 121:4718-4728.
10. Franke W.W., Schmid E., Mittnacht S., Grund C., Jorcano J.L. Integration of different keratins into the same filament system after microinjection of mRNA for epidermal keratins into kidney epithelial cells. Cell 1984, 36:813-825.
11. Pinkus G.S., Warhol M.J., O'Connor E.M., Etheridge C.L., Fujiwara K. Immunohistochemical localization of smooth muscle myosin in human spleen, lymph node, and other lymphoid tissues. Unique staining patterns in splenic white pulp and sinuses, lymphoid follicles, and certain vasculature, with ultrastructural correlations. Am J Pathol 1986, 123:440-453.
12. Gretz J.E., Anderson A.O., Shaw S. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev 1997, 156:11-24.
13. Bajenoff M., Egen J.G., Koo L.Y., Laugier J.P., Brau F., Glaichenhaus N., et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006, 25:989-1001.
14. Thomazy V.A., Vega F., Medeiros L.J., Davies P.J., Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell types. Am J Pathol 2003, 163:165-174.
15. Vega F., Coombes K.R., Thomazy V.A., Patel K., Lang W., Jones D. Tissue-specific function of lymph node fibroblastic reticulum cells. Pathobiology 2006, 73:71-81.
16. Acton S.E., Farrugia A.J., Astarita J.L., Mourao-Sa D., Jenkins R.P., Nye E., et al. Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature 2014, 514:498-502.
17. Acton S.E., Astarita J.L., Malhotra D., Lukacs-Kornek V., Franz B., Hess P.R., et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 2012, 37:276-289.
18. Sixt M., Kanazawa N., Selg M., Samson T., Roos G., Reinhardt D.P., et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005, 22:19-29.
19. Gretz J.E., Kaldjian E.P., Anderson A.O., Shaw S. Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. J Immunol 1996, 157:495-499.
20. Corcione A., Arduino N., Ferretti E., Raffaghello L., Roncella S., Rossi D., et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res 2004, 10:964-971.
21. Lopez-Giral S., Quintana N.E., Cabrerizo M., Alfonso-Perez M., Sala-Valdes M., De Soria V.G., et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004, 76:462-471.
22. Rehm A., Anagnostopoulos I., Gerlach K., Broemer M., Scheidereit C., Johrens K., et al. Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int J Cancer 2009, 125:2367-2374.
23. Rehm A., Mensen A., Schradi K., Gerlach K., Wittstock S., Winter S., et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011, 118:1020-1033.
24. Vega F., Medeiros L.J., Lang W.H., Mansoor A., Bueso-Ramos C., Jones D. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br J Haematol 2002, 117:569-576.
25. Cyster J.G., Ansel K.M., Reif K., Ekland E.H., Hyman P.L., Tang H.L., et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 2000, 176:181-193.
26. Matas-Cespedes A., Rodriguez V., Kalko S.G., Vidal-Crespo A., Rosich L., Casserras T., et al. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib). Clin Cancer Res 2014, 20:3458-3471.
27. Martinez A., Carreras J., Campo E. The follicular lymphoma microenvironment: from tumor cell to host immunity. Curr Hematol Malig Rep 2008, 3:179-186.
28. Yagi K., Yamamoto K., Umeda S., Abe S., Suzuki S., Onishi I., et al. Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells. Histopathology 2013, 62:414-420.
29. Lwin T., Lin J., Choi Y.S., Zhang X., Moscinski L.C., Wright K.L., et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010, 116:5228-5236.
30. Pedersen I.M., Kitada S., Leoni L.M., Zapata J.M., Karras J.G., Tsukada N., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
31. Jones D., Jorgensen J.L., Shahsafaei A., Dorfman D.M. Characteristic proliferations of reticular and dendritic cells in angioimmunoblastic lymphoma. Am J Surg Pathol 1998, 22:956-964.
32. Belz G.T., Nutt S.L. Transcriptional programming of the dendritic cell network. Nat Rev Immunol 2012, 12:101-113.
33. Huang G., Wang Y., Chi H. Control of T cell fates and immune tolerance by p38alpha signaling in mucosal CD103+ dendritic cells. J Immunol 2013, 191:650-659.
34. Hall J.A., Grainger J.R., Spencer S.P., Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity 2011, 35:13-22.
35. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4:e4992.
36. Wang W., Du Z., Yan J., Ma D., Shi M., Zhang M., et al. Mesenchymal stem cells promote liver regeneration and prolong survival in small-for-size liver grafts: involvement of C-Jun N-terminal kinase, cyclin D1, and NF-kappaB. PLoS ONE 2014, 9:e112532.
37. Ame-Thomas P., Maby-El Hajjami H., Monvoisin C., Jean R., Monnier D., Caulet-Maugendre S., et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007, 109:693-702.
38. Burger J.A., Burger M., Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94:3658-3667.
39. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931.
40. Kim Y.R., Eom K.S. Simultaneous inhibition of CXCR4 and VLA-4 exhibits combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells. Immune Netw 2014, 14:296-306.
41. Kurtova A.V., Tamayo A.T., Ford R.J., Burger J.A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613.
42. Brady M.T., Hilchey S.P., Hyrien O., Spence S.A., Bernstein S.H. Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells. PLOS ONE 2014, 9:e97597.
43. Ding W., Nowakowski G.S., Knox T.R., Boysen J.C., Maas M.L., Schwager S.M., et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009, 147:471-483.
44. Lutzny G., Kocher T., Schmidt-Supprian M., Rudelius M., Klein-Hitpass L., Finch A.J., et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23:77-92.
45. Cardesa-Salzmann T.M., Colomo L., Gutierrez G., Chan W.C., Weisenburger D., Climent F., et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011, 96:996-1001.
46. Ruan J., Hajjar K., Rafii S., Leonard J.P. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009, 20:413-424.
47. Aguirre Palma L.M., Gehrke I., Kreuzer K.A. Angiogenic factors in chronic lymphocytic leukaemia (CLL): where do we stand?. Crit Rev Oncol/Hematol 2015, 93:225-236.
48. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
49. Kay N.E., Bone N.D., Tschumper R.C., Howell K.H., Geyer S.M., Dewald G.W., et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002, 16:911-919.
50. Potti A., Ganti A.K., Kargas S., Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002, 22:2899-2901.
51. Gratzinger D., Zhao S., Marinelli R.J., Kapp A.V., Tibshirani R.J., Hammer A.S., et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007, 170:1362-1369.
52. Dimtsas G.S., Georgiadi E.C., Karakitsos P., Vassilakopoulos T.P., Thymara I., Korkolopoulou P., et al. Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leuk Lymphoma 2014, 55:558-564.
53. Bardelli M., Leucci E., Schurfeld K., Bellan C., Passiatore G., Rocchigiani M., et al. VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues. Leuk Lymphoma 2007, 48:2014-2021.
54. Salven P., Orpana A., Teerenhovi L., Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000, 96:3712-3718.
55. Ho C.L., Sheu L.F., Li C.Y. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003, 7:1-8.
56. Blonska M., Zhu Y., Chuang H.H., You M.J., Kunkalla K., Vega F., et al. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 2015, 125:981-991.
57. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
58. Ruan J., Luo M., Wang C., Fan L., Yang S.N., Cardenas M., et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013, 121:5192-5202.
59. Streubel B., Chott A., Huber D., Exner M., Jager U., Wagner O., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351:250-259.
60. Ribatti D., Molica S., Vacca A., Nico B., Crivellato E., Roccaro A.M., et al. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2003, 17:1428-1430.
61. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
62. Stevenson F.K., Stevenson G.T. Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood 2012, 119:3659-3667.
63. Riihijarvi S., Fiskvik I., Taskinen M., Vajavaara H., Tikkala M., Yri O., et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 2015, 100:238-245.
64. de Jong D., Koster A., Hagenbeek A., Raemaekers J., Veldhuizen D., Heisterkamp S., et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009, 94:70-77.
65. Taskinen M., Karjalainen-Lindsberg M.L., Nyman H., Eerola L.M., Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007, 13:5784-5789.
66. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
67. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
68. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
69. Filip A.A., Cisel B., Koczkodaj D., Wasik-Szczepanek E., Piersiak T., Dmoszynska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages. Blood Cells Mol Dis 2013, 50:263-270.
70. Filip A.A., Cisel B., Wasik-Szczepanek E. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes. Clin Exp Med 2015, 15:73-83.
71. Arruga F., Gizdic B., Serra S., Vaisitti T., Ciardullo C., Coscia M., et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2014, 28:1060-1070.
72. Bulian P., Shanafelt T.D., Fegan C., Zucchetto A., Cro L., Nuckel H., et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014, 32:897-904.
73. Fiorcari S., Martinelli S., Bulgarelli J., Audrito V., Zucchini P., Colaci E., et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica 2015, 100:253-262.
74. Schulz A., Durr C., Zenz T., Dohner H., Stilgenbauer S., Lichter P., et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood 2013, 121:2503-2511.
75. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
76. Zucchetto A., Benedetti D., Tripodo C., Bomben R., Dal Bo M., Marconi D., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009, 69:4001-4009.
77. Sivina M., Hartmann E., Kipps T.J., Rassenti L., Krupnik D., Lerner S., et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011, 117:1662-1669.
78. Carreras J., Lopez-Guillermo A., Fox B.C., Colomo L., Martinez A., Roncador G., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006, 108:2957-2964.
79. Rawal S., Chu F., Zhang M., Park H.J., Nattamai D., Kannan S., et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013, 190:6681-6693.
80. Glas A.M., Knoops L., Delahaye L., Kersten M.J., Kibbelaar R.E., Wessels L.A., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007, 25:390-398.
81. Byrd J.C., Kipps T.J., Flinn I.W., Cooper M., Odenike O., Bendiske J., et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:2136-2142.
82. Greaves P., Clear A., Owen A., Iqbal S., Lee A., Matthews J., et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 2013, 122:2856-2863.
83. Yang C., Lee H., Pal S., Jove V., Deng J., Zhang W., et al. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS ONE 2013, 8:e64159.
84. Shain K.H., Dalton W.S., Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015, [Epub ahead of print].
85. Calvo K.R., Dabir B., Kovach A., Devor C., Bandle R., Bond A., et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood 2008, 112:3818-3826.
86. Castillo R., Mascarenhas J., Telford W., Chadburn A., Friedman S.M., Schattner E.J. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 2000, 14:292-298.
87. Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013, 40:336-343.
88. Onder L., Narang P., Scandella E., Chai Q., Iolyeva M., Hoorweg K., et al. IL-7-producing stromal cells are critical for lymph node remodeling. Blood 2012, 120:4675-4683.
89. Corcoran A.E., Riddell A., Krooshoop D., Venkitaraman A.R. Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor. Nature 1998, 391:904-907.
90. Treanor L.M., Zhou S., Janke L., Churchman M.L., Ma Z., Lu T., et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med 2014, 211:701-713.
91. Silva A., Laranjeira A.B., Martins L.R., Cardoso B.A., Demengeot J., Yunes J.A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011, 71:4780-4789.
92. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
93. Yee C., Biondi A., Wang X.H., Iscove N.N., de Sousa J., Aarden L.A., et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989, 74:798-804.
94. Zhang L., Yang J., Qian J., Li H., Romaguera J.E., Kwak L.W., et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012, 120:3783-3792.
95. Ding B.B., Yu J.J., Yu R.Y., Mendez L.M., Shaknovich R., Zhang Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111:1515-1523.
96. Lam L.T., Wright G., Davis R.E., Lenz G., Farinha P., Dang L., et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008, 111:3701-3713.
97. Scuto A., Kujawski M., Kowolik C., Krymskaya L., Wang L., Weiss L.M., et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011, 71:3182-3188.
98. Blonska M., Lin X. CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev 2009, 228:199-211.
99. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010, 2:a000109.
100. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
101. Gascoyne R.D. Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma 2003, 44(Suppl. 3):S13-S20.
102. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dorken B., Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999, 18:943-953.
103. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
104. Sun S.C. The noncanonical NF-kappaB pathway. Immunol Rev 2012, 246:125-140.
105. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
106. Ho L., Davis R.E., Conne B., Chappuis R., Berczy M., Mhawech P., et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005, 105:2891-2899.
107. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
108. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
109. Lim K.H., Yang Y., Staudt L.M. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies. Immunol Rev 2012, 246:359-378.
110. Medina D.J., Goodell L., Glod J., Gelinas C., Rabson A.B., Strair R.K. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica 2012, 97:1255-1263.
111. Lwin T., Crespo L.A., Wu A., Dessureault S., Shu H.B., Moscinski L.C., et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia 2009, 23:170-177.
112. Lwin T., Hazlehurst L.A., Li Z., Dessureault S., Sotomayor E., Moscinski L.C., et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007, 21:1521-1531.
113. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A.T., Yoshimura L.C., Ford R.J. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009, 113:4627-4636.
114. Rauch M., Tussiwand R., Bosco N., Rolink A.G. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS ONE 2009, 4:e5456.
115. Lam L.T., Davis R.E., Pierce J., Hepperle M., Xu Y., Hottelet M., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11:28-40.
116. Fontan L., Melnick A. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. Clin Cancer Res 2013, 19:6662-6668.
117. McMahon A.P., Ingham P.W., Tabin C.J. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003, 53:1-114.
118. Kalderon D. Transducing the hedgehog signal. Cell 2000, 103:371-374.
119. Dierks C., Grbic J., Zirlik K., Beigi R., Englund N.P., Guo G.R., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007, 13:944-951.
120. Hegde G.V., Peterson K.J., Emanuel K., Mittal A.K., Joshi A.D., Dickinson J.D., et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res 2008, 6:1928-1936.
121. Peacock C.D., Wang Q., Gesell G.S., Corcoran-Schwartz I.M., Jones E., Kim J., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007, 104:4048-4053.
122. Kim J.E., Singh R.R., Cho-Vega J.H., Drakos E., Davuluri Y., Khokhar F.A., et al. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 2009, 22:1312-1320.
123. Singh R.R., Cho-Vega J.H., Davuluri Y., Ma S., Kasbidi F., Milito C., et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 2009, 69:2550-2558.
124. Kobune M., Takimoto R., Murase K., Iyama S., Sato T., Kikuchi S., et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009, 100:948-955.
125. Lin T.L., Wang Q.H., Brown P., Peacock C., Merchant A.A., Brennan S., et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS ONE 2010, 5:e15262.